Clinical trial teams rarely struggle because they have no data. More often, they struggle because the right people cannot review the right clinical trial data quickly enough to spot issues, assess risk, and make decisions while the study is still moving.
Clinical data review is the process of examining accumulating clinical trial data to check whether it is accurate, complete, consistent, and fit for its intended use. It is often framed against the ALCOA++ principles for data quality and integrity: attributable, legible, contemporaneous, original, and accurate, plus complete, consistent, enduring, available when needed, and traceable. In practice, that goes well beyond checking whether fields have been completed correctly. The real purpose is to help teams decide whether the data reflects what happened in the study well enough to support subject safety, trial conduct, and reliable interpretation later on.
That distinction matters because a clinical data reviewer is not only looking for isolated data entry problems, but also for discrepancies, unusual patterns, missing context, and signals that could affect medical review, monitoring, or confidence in the study results. Seen that way, clinical data review sits at the intersection of quality control, risk decision, and decision support. Those principles apply across data from paper-based records, eSource, hybrid collection models, and other sources such as medical images and laboratory equipment read-outs. In practical terms, the aim is not only patient safety and sound trial decisions, but also transparency, research integrity, regulatory compliance, and scientific validity.
Older models of clinical data review were heavily manual. Review often depended on paper records, handwritten case report forms, site visits, and study-level listings produced after the fact. That approach was more workable when studies generated less data from fewer sources, but it was also slow, labour-intensive, and prone to delay and human error.
The deeper issue is that modern trials no longer fit that model. Clinical trial data now comes from a much wider technology ecosystem, including electronic data capture (EDC), ePRO and eCOA tools, central labs, biomarkers, imaging, sensors, wearable devices, and electronic medical record sources. As data volume and complexity increase, static listings and late-stage reports become less useful, because the study may already have moved on by the time the question is answered.
Therefore, the shift is better understood not as a cosmetic technology upgrade, but as a change in review logic. When data arrives faster, from more sources, and serves more audiences, review has to move closer to the pace of study execution.
Modern clinical data review is typically more electronic, centralised, and continuous than older approaches. Rather than waiting for periodic outputs, teams increasingly work with near real-time data feeds, unified review environments, automated checks, alerts, and visual tools that allow reviewers to move from high-level trends to subject-level detail. In many studies, data is now captured directly in electronic form through direct data capture or electronic data capture systems, and managed within clinical data management systems that support ongoing review across sites and stakeholders.
A key part of that shift is risk-based focus. Instead of reviewing every data point in the same way, current review models increasingly prioritise critical data, important relationships, and emerging anomalies that matter most for patient safety, protocol conduct, or confidence in the results. This reflects a broader move away from treating all data equally can dilute attention and increase the risk of missing important quality gaps in critical data.
Dashboards and interactive analytics support that model by giving reviewers both overview and drill-down capability across population-level patterns, subject-level detail, and related domain comparisons such as labs, adverse events, medications, and protocol deviations. Modern review increasingly depends on a dynamic environment for interrogation, not just a report output.
A clinical data reviewer usually needs to assess more than one domain at once. Depending on the study and the reviewer’s role, that can include:
In practice, the job Is often to understand how those data relate to one another, rather than reviewing each domain in isolation.
That cross-domain view matters because important findings do not always appear inside a single dataset. A safety concern may only become obvious when lab changes, adverse events, dose history, and subject timing are considered together. Review may also need to extend beyond patient data alone, including audit trails that show how the protocol is being operationalised and how data is being collected. So, when people ask what a clinical data review is, the most useful answer is not just ‘checking data quality’. It is the structured review of clinical trial data to identify whether the data, taken together, supports safe oversight and credible study decisions.
The recurring challenge across clinical trials is not simply ‘too much data’. It is the combination of fragmented sources, delayed access, inflexible reporting, and the need to identify issues early enough to matter. When review teams depend on other functions or vendors to generate manual outputs, delays increase, collaboration becomes harder, and analyses may be difficult to reproduce or compare consistently across domains.
Common operational barriers
Some of the most common pressures include:
These matter because they support earlier identification of safety, efficacy, or data quality issues. Common pain points also include:
The changing data environment adds another layer of difficulty. Volume and velocity are rising with continuous data sources such as sensors and wearables, while variety is expanding through decentralised trial inputs, real-world data, and non-standardised sources that do not always fit conventional research data structures. As a result, one-size-fits-all review models are harder to sustain.
Clinical data review sits inside wider clinical data management and study oversight rather than outside it. Clinical data management refers to the broader lifecycle of data used in or generated by a clinical trial, and clinical data review sits within that wider framework.
A practical implication is that the review process should be defined up front in the data management plan and, where relevant, reflected in the protocol. That includes tailoring the approach to the study design, case report forms, data types, collection methods, and software tools in use.
It also sits alongside monitoring and governance activities. Modern review supports medical monitoring, progress assessment, protocol decisions, anomaly review, and risk-based monitoring, which means different authorised reviewers may need access to the same underlying data through different review lenses. That helps explain why collaboration, shared visibility, and usable presentation formats matter so much in practice.
Put simply, clinical data review is not just something that happens after data collection. It is part of how teams oversee the study while it is running.
A related practical consideration is interoperability. Data standards and formats such as HL7, FHIR, CDISC, CDASH, and SDTM are relevant because smoother integration across systems and countries depends in part on how consistently data is structured and exchanged. Data integrity and privacy expectations also sit in the background here, including adherence to applicable regulatory requirements and patient confidentiality obligations.
Clinical data review is increasingly associated with intelligent automation, machine learning, and strategies that move beyond simple filtering and trending toward more advanced visual and analytical review approaches. It also points to increasing automation, improved integration of varied data sources, and a more supervisory human role as intelligent tools mature. That broader integration picture increasingly includes EHRs, real-world data, wearables, mobile apps, and clinical trial data used together to build a fuller view of patient outcomes.
Even so, the practical takeaway is not that automation replaces judgement. It is that the review process is becoming more assisted, more scalable, and more dependent on timely access to integrated data. As more trials use decentralised elements, connected devices, or other complex sources, the value of fit-for-purpose review design and human interpretation is likely to increase rather than disappear.
Regulatory expectations are also likely to become more explicit as electronic records, electronic signatures, computerised systems, audit trails, and AI-supported processing become more central to trial operations. In that environment, clearer rules around standardisation, audit trail formats, data security, and the ethical use of AI in clinical data management are likely to matter more, not less.
Clinical data review is best understood as the ongoing evaluation of clinical trial data so teams can judge whether it is reliable, meaningful, and actionable while the study is still active.
The main shift has been away from retrospective, paper- or listing-led review towards more centralised, risk-based, and near real-time approaches built for more complex and faster-moving studies. Better tools support that shift, but the main objective remains clearer visibility into the data and faster recognition of what matters.
Quanticate’s clinical data management team supports sponsors with practical, study-specific data review strategies designed to improve visibility, maintain data quality, and support confident decision-making throughout trial delivery. Whether you need support with data management planning, ongoing review workflows, or broader oversight across complex data sources, our team can help you build a process that is both robust and workable. Request a consultation today.